Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06576427 · ClinicalTrials.gov registry record · NA

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

A NA study of Pulmonary Embolism, sponsored by Jupiter Endovascular.

Active
Registry status
NA
Development phase
123
Enrollment target
20
Study locations

NCT06576427: Active NA study of Pulmonary Embolism, sponsored by Jupiter Endovascular.

NCT06576427 is a NA study of Pulmonary Embolism that is active but no longer recruiting, run by Jupiter Endovascular. The registered enrollment target is 123 participants, below the 3,056-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06576427, a NA study of Pulmonary Embolism, is active but no longer recruiting, sponsored by Jupiter Endovascular.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
123 participants
Enrollment target
20
Study locations

Study Summary

This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.

Primary Outcome

Reduction in RV/LV ratio from baseline to 48 hours or discharge by (core lab assessed) CT angiography

Conditions Studied

Interventions

  • DEVICE Vertex Pulmonary Embolectomy System

Study Locations (20)

New York

  • NYU Langone Health - New York
  • Northwell Health - Staten Island
  • Westchester Medical Center - Valhalla

North Carolina

  • University of North Carolina - Chapel Hill
  • Duke University - Durham
  • Wake Forest Medical Center - Winston-Salem

Pennsylvania

  • Penn Presbyterian - Philadelphia
  • UPMC Presbyterian - Pittsburgh
  • St Clair Health - Pittsburgh

Michigan

  • Henry Ford Hospital - Detroit
  • Henry Ford St John - Detroit

Other

  • Medical University of Vienna - Vienna
  • St. John Paul II Hospital - Krakow

Connecticut

  • Hartford Hospital - Hartford

Florida

  • Ascension Sacred Heart - Pensacola

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2024-10-15
Est. Completion 2026-03
Phase NA
Jupiter Endovascular

1 total trials

What the registry record for NCT06576427 still lists

NCT06576427 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 3,056-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 1 intervention - of which Vertex Pulmonary Embolectomy System is the first listed.

NCT06576427 names 20 study sites across 12 states, led by New York, North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06576427 about?

NCT06576427 is a clinical study titled "Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II". This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.

What is the current status of trial NCT06576427?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 123 participants. The study started on 2024-10-15. Estimated completion is 2026-03.

What conditions does trial NCT06576427 study?

This clinical trial studies the following conditions: Pulmonary Embolism.

What interventions are being tested in trial NCT06576427?

The interventions under investigation include: Vertex Pulmonary Embolectomy System (DEVICE).

Who is sponsoring clinical trial NCT06576427?

This trial is sponsored by Jupiter Endovascular, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06576427 being conducted?

This trial has 20 study locations across Connecticut, Florida, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Embolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06576427's enrollment target sits among peer trials

123 32nd of 48 higher than 17 of 48 other Pulmonary Embolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05285891 · 123 participants · Phase 4

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  • NCT05334368 · 123 participants · Phase 3

    Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

  • NCT06088355 · 123 participants · NA

    Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

  • NCT06111131 · 123 participants · NA

    Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06576427, the US trial registry maintained by the National Library of Medicine. NCT06576427 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.